Projects per year
Abstract
Background: End-stage kidney disease is a major health burden
worldwide and is a strong risk factor for sudden cardiac death.
Polyphenol supplementation has been suggested to reduce
cardiovascular risk factors in haemodialysis patients. The aim
of this systematic review was to pool and evaluate the current
evidence for polyphenol interventions for cardiovascular risk
reduction in haemodialysis patients.
Methods: The Cochrane Library, MEDLINE (vis Scopus),
Embase, and CINAHL were searched for double-blind placebocontrolled randomised trials up until 29 June 2017. PhenolExplorer 3.6 database was used to inform known polyphenolrich interventions. Treatment effect was quantified by metaanalysis for measures of lipid profile, inflammation, oxidative
stress, and blood pressure. Risk of bias was assessed using
the Cochrane Collaboration Risk of Bias tool and quality of the
body of evidence assessed by the GRADE methodology.
Results: Twelve studies were included which utilised the
polyphenol-rich supplements soy, cocoa, pomegranate,
grape, and turmeric in powder or juice form. Risk of bias
across studies was mostly low; though randomisation and
allocation was poorly described in most studies. Polyphenol
interventions significantly improved diastolic blood pressure
(MD -5.62mmHg [95% CI -8.47, -2.78]; I2=2%; p=0.0001; n=4
studies; n=245 participants; GRADE: moderate), triglyceride
levels (MD -26.52mg/dL [95% CI -47.22, -5.83]; I2=57%;
p=0.01; n=4 studies; n=191 participants; GRADE: very low),
and oxidative stress (myeloperoxidase) (SMD -90.1 [95%
CI -135.8, -44.4]; I2=0%; p=0.0001; n=2 studies; n=126
participants; GRADE: high). Improvements in other measures
of haemodynamics and lipid profiles were significant with
large effect sizes in sub-samples with hypertension and
hypercholesterolaemia respectively (not pooled).
Conclusions: The results suggest polyphenol-rich
supplementation may improve cardiovascular risk markers
in haemodialysis patients, especially those with existing
cardiovascular disease. Further studies of sufficient
duration are required to establish efficacy and allow for
recommendation of particular polyphenol types and dosages.
worldwide and is a strong risk factor for sudden cardiac death.
Polyphenol supplementation has been suggested to reduce
cardiovascular risk factors in haemodialysis patients. The aim
of this systematic review was to pool and evaluate the current
evidence for polyphenol interventions for cardiovascular risk
reduction in haemodialysis patients.
Methods: The Cochrane Library, MEDLINE (vis Scopus),
Embase, and CINAHL were searched for double-blind placebocontrolled randomised trials up until 29 June 2017. PhenolExplorer 3.6 database was used to inform known polyphenolrich interventions. Treatment effect was quantified by metaanalysis for measures of lipid profile, inflammation, oxidative
stress, and blood pressure. Risk of bias was assessed using
the Cochrane Collaboration Risk of Bias tool and quality of the
body of evidence assessed by the GRADE methodology.
Results: Twelve studies were included which utilised the
polyphenol-rich supplements soy, cocoa, pomegranate,
grape, and turmeric in powder or juice form. Risk of bias
across studies was mostly low; though randomisation and
allocation was poorly described in most studies. Polyphenol
interventions significantly improved diastolic blood pressure
(MD -5.62mmHg [95% CI -8.47, -2.78]; I2=2%; p=0.0001; n=4
studies; n=245 participants; GRADE: moderate), triglyceride
levels (MD -26.52mg/dL [95% CI -47.22, -5.83]; I2=57%;
p=0.01; n=4 studies; n=191 participants; GRADE: very low),
and oxidative stress (myeloperoxidase) (SMD -90.1 [95%
CI -135.8, -44.4]; I2=0%; p=0.0001; n=2 studies; n=126
participants; GRADE: high). Improvements in other measures
of haemodynamics and lipid profiles were significant with
large effect sizes in sub-samples with hypertension and
hypercholesterolaemia respectively (not pooled).
Conclusions: The results suggest polyphenol-rich
supplementation may improve cardiovascular risk markers
in haemodialysis patients, especially those with existing
cardiovascular disease. Further studies of sufficient
duration are required to establish efficacy and allow for
recommendation of particular polyphenol types and dosages.
| Original language | English |
|---|---|
| Pages | 31 |
| Publication status | Published - 2017 |
| Event | 43rd Annual Scientific Meeting of the Australasian Society for Parenteral and Enteral Nutrition: Collaboration in Clinical Nutrition – Evidence Based Nutrition for Improving Patient Outcomes - Royal Pines Conference Centre, Gold Coast, Australia Duration: 16 Nov 2017 → 18 Nov 2017 Conference number: 43rd |
Conference
| Conference | 43rd Annual Scientific Meeting of the Australasian Society for Parenteral and Enteral Nutrition |
|---|---|
| Abbreviated title | AuSPEN 2017 |
| Country/Territory | Australia |
| City | Gold Coast |
| Period | 16/11/17 → 18/11/17 |
Access to Document
Fingerprint
Dive into the research topics of 'The effect of polyphenols on cardiovascular risk factors in haemodialysis: a systematic review and meta-analysis'. Together they form a unique fingerprint.Related Projects
- 1 Active
-
Nutrition for Chronic Disease and Disability: Research to improve health related quality of life and bring forward the under-represented voice
Reidlinger, D., Davidson, A., Campbell, K., Kelly, J., Mayr, H., English, C., Odgers-Jewell, K., MacKenzie-Shalders, K., Van der Meij, B., Crichton, M., Marshall, S., Turner, C., Marx, W., Utter, J., Maugeri, B. & Tang, X.
1/01/14 → 31/08/30
Project: Research